Butterfly Network Inc. (NYSE: BFLY), a digital health company pioneering portable ultrasound technology, saw its stock soar 5.31% on Wednesday after its third-generation handheld ultrasound device, Butterfly iQ3, was honored with the Best Medical Technology Award at the 2024 Prix Galien USA Awards.
The Prix Galien Awards, regarded as the "Nobel Prize of Life Sciences," recognize outstanding achievements in improving global human health through innovative drugs and treatments. Butterfly's recognition highlights the company's commitment to making ultrasound imaging more affordable, sustainable, and scalable through its pioneering Ultrasound-on-Chip technology.
The Butterfly iQ3 represents a leap forward in ultrasound technology, offering clinicians portable, semiconductor-based imaging with premium handheld quality. Built on Butterfly's proprietary P4.3 semiconductor – its most powerful Ultrasound-on-Chip platform to date – the iQ3 represents a digital revolution in the ultrasound industry, enabling practitioners to make faster, more accurate decisions, and ultimately transforming patient care on a global scale.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。